

DAFTAR PUSTAKA

1. Libby P. The changing landscape of atherosclerosis. *Nature*. 2021;592(7855):524–33.
2. Lechner K, von Schacky C, McKenzie AL, Worm N, Nixdorff U, Lechner B. Lifestyle factors and high-risk atherosclerosis: Pathways and mechanisms beyond traditional risk factors. *Eur J Prev Cardiol*. 2020;
3. Kim H, Kim S, Han S, Rane PP, Fox KM, Qian Y. Prevalence and incidence of atherosclerotic cardiovascular disease and its risk factors in Korea: a nationwide population-based study. . *BMC Public Health*. 2019;19(1):1–11.
4. Maharani A, Praveen D, Oceandy D, Tambupolon G, Patel A. Cardiovascular disease risk factor prevalence and estimated 10-year cardiovascular risk scores in Indonesia: The SMARTHealth Extend Study. *PLoS One*. 2019;14(4):e0215219.
5. Ford TJ, Corcoran D, Berry C. Stable coronary syndromes: pathophysiology, diagnostic advances and therapeutic need. *Heart*. 2018;104 (4):284–92. *Heart*. 2018;104 (4):284–92.
6. Singh A, Museedi AS, Grossman SA. Acute coronary syndrome. In: *StatPearls [Internet]*. Treasure Island (FL): StatPearls Publishing; 2017.
7. Kementrian Kesehatan RI. Hasil Utama Riset Kesehatan Dasar (RISKESDAS). . Jakarta: Kemenkes; 2013.
8. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Vol. 42, *European Heart Journal*. Oxford University Press; 2021. p. 3227–337.
9. Farzadfar F. Cardiovascular disease risk prediction models: challenges and perspectives. 2019.
10. Kaptoge S, Pennells L, De Bacquer D, Cooney MT, Kavousi M, Stevens G, et al. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. *Lancet Glob Health*. 2019 Oct 1;7(10):e1332–45.
11. Lisowska A, Knapp M, Tycińska A, Motybel E, Kamiński K, Świłcecki P. Predictive value of Galektin-3 for the occurrence of coronary artery disease and prognosis after myocardial infarction and its association with carotid IMT values in these patients: A mid-term prospective cohort study. *Atherosclerosis*. 2016;246:309–17.
12. Jabbar HD, Al-Haleem MR, Mohammed RJ. Galektin-3 as a diagnostic biomarker in patients with chronic stable heart failure. *HIV Nursing*. 2023;23(1): 825-29.
13. Grandin EW, Jarolim P, Murphy SA, Ritterova L, Cannon CP, Braunwald E, et al. Galektin-3 and the development of heart failure after acute coronary syndrome: Pilot experience from PROVE IT-TIMI 22. *Clin Chem*. 2012 Jan;58(1):267–73.
14. Asleh R, Enriquez-Sarano M, Jaffe AS, Manemann SM, Weston SA, Jiang R, et al.

- Galektin-3 Levels and Outcomes After Myocardial Infarction: A Population-Based Study. *J Am Coll Cardiol*. 2019 May 14;73(18):2286–95.
15. Martin-Reyes R, Franco-Pelaez JA, Lorenzo S, Gonzalez-Casaus ML, Acena AMP, Carda R, et al. Plasma levels of monocyte chemoattractant protein-1, n-terminal fragment of brain natriuretic peptide and calcidiol are independently associated with the complexity of coronary artery disease. *PLoS One*. 2016 May 1;11(5).
 16. O'Donoghue ML, Morrow DA, Cannon CP, Jarolim P, Desai NR, Sherwood MW, et al. Multimarker Risk Stratification in Patients With Acute Myocardial Infarction. *J Am Heart Assoc*. 2016 May 1;5(5).
 17. Gao Z, Liu Z, Wang R, Zheng Y, Li H, Yang L. Galektin-3 Is a Potential Mediator for Atherosclerosis. *J Immunol Res*. 2020;2020.
 18. Fernández-Alvarez V, Linares Sánchez M, López Alvarez F, Suárez Nieto C, Mäkitie AA, Olsen KD, et al. Evaluation of Intima-Media Thickness and Arterial Stiffness as Early Ultrasound Biomarkers of Carotid Artery Atherosclerosis. *Cardiol Ther*. 2022 Jun 1;11(2):231–47.
 19. Kurkowska-Jastrzębska I, Karliński MA, Błazejewska-Hyzorek B, Sarzyńska-Długosz I, Filipiak KJ, Członkowska A. Carotid intima media thickness and blood biomarkers of atherosclerosis in patients after stroke or myocardial infarction. *Croat Med J*. 2016;57(6):548–57.
 20. Bauer M, Caviezel S, Teynor A, Erbel R, Mahabadi AA, Schmidt-Trucksäss A. Carotid intima-media thickness as a biomarker of subclinical atherosclerosis. Vol. 142, *Swiss Medical Weekly*. 2012.
 21. Wang, Y., Bulloch, G., Huang, Y. *et al.* Determinants of incident atherosclerotic cardiovascular disease events among individuals with type 2 diabetic microvascular complications in the UK: a prospective cohort study. *Diabetol Metab Syndr*. 2023;15: p178.
 22. Weng, W., Tian, Y., Kong, S.X. *et al.* Impact of atherosclerotic cardiovascular disease on healthcare resource utilization and costs in patients with type 2 diabetes mellitus in a real-world setting. *Clin Diabetes Endocrinol* 6, 5; 2020.
 23. Hara A, Niwa M, Noguchi K, Kanayama T, Niwa A, Matsuo M, et al. Galektin-3 as a next-generation biomarker for detecting early stage of various diseases. Vol. 10, *Biomolecules*. MDPI AG; 2020.
 24. Yang RY, Rabinovich GA, Liu FT. Galectins: structure, function and therapeutic potential. *Expert Rev Mol Med*. 2008;10.
 25. Nabi IR, Shankar J, Dennis JW. The galectin lattice at a glance. *J Cell Sci*. 2015;128(13):2213–9.
 26. Johannes L, Jacob R, Leffler H. Galectins at a glance. *J Cell Sci*. 2018 May 1;131(9).

27. Dong R, Zhang M, Hu Q, Zheng S, Soh A, Zheng Y, et al. Galektin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review). Vol. 41, *International Journal of Molecular Medicine*. Spandidos Publications; 2018. p. 599–614.
28. Li M, Yuan Y, Guo K, Lao Y, Huang X, Feng L. Value of Galektin-3 in acute myocardial infarction. *Am J Cardiovasc Drugs*. 2020;20(4):333–42. *Am J Cardiovasc Drugs*. 2020;20(4):333–42.
29. Amin H, Amin L, Wijaya Eka P. Galektin-3: a novel biomarker for the prognosis of heart failure. *Clujul Med*. 2017;90(2):129–32.
30. Blanda V, Bracale UM, Di Taranto MD, Fortunato G. Galektin-3 in cardiovascular diseases. Vol. 21, *International Journal of Molecular Sciences*. MDPI AG; 2020. p. 1–18.
31. Sciacchitano S, Lavra L, Morgante A, Olivieri A, Magi F, De Francesco GP, et al. Galektin-3: One molecule for an alphabet of diseases, from A to Z. Vol. 19, *International Journal of Molecular Sciences*. MDPI AG; 2018.
32. Dings RPM, Miller MC, Griffin RJ, Mayo KH. Galectins as molecular targets for therapeutic intervention. Vol. 19, *International Journal of Molecular Sciences*. MDPI AG; 2018.
33. Chen SC, Kuo P. The Role of Galektin-3 in the Kidneys. *Int J Mol Sci*. 2016;17(4):565.
34. DK Hsu, CA Dowling, KC Jeng, JT Chen, RY Yang, FT Liu. Galektin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. *Int. J. Cancer* 81:519–526, 1999. [https://doi.org/10.1002/\(SICI\)1097-0215\(19990517\)81:4%3C519::AID-IJC3%3E3.0.CO;2-0](https://doi.org/10.1002/(SICI)1097-0215(19990517)81:4%3C519::AID-IJC3%3E3.0.CO;2-0). *Int J Cancer*. 1999;81:519–26.
35. Gudowska M, Gruszewska M, Cylwik B, Panasiuk A, Rogalska M, Flisiak R. Galektin-3 Concentration in Liver Diseases. *Ann Clin Lab Sci*. 2015;45(6):669–73.
36. Nish Y, Sano H, Kawashima T, Okada T, Kuroda T, Kikkawa K. Role of Galektin-3 in Human Pulmonary Fibrosis. *Allergy immunology International*. Volume 56, Issue 1, 2007, P:57-65. <https://doi.org/10.2332/allergolint.O-06-449>. *Allergy immunology International*. 2007;56(1):57–65.
37. Sadlonova M, Meyer T, Binder L, Wachter R, Edelmann F, Herrmann-Lingen C. Higher galektin-3 levels are independently associated with lower anxiety in patients with risk factors for heart failure. *Biopsychosoc Med*. 2020 Oct;14:24.
38. Insel PA, Murray F, Yokoyama U, Romano S, Yun H, Brown L, et al. Themed Section: Novel cAMP Signalling Paradigms cAMP and Epac in the regulation of tissue fibrosis LINKED ARTICLES. 2012; Available from: <http://dx.doi.org/10.1111/bph.2012.166.issue-2>
39. Ibarrola J, Matilla L, Martínez-Martínez E, Gueret A, Fernández-Celis A, Henry JP, et al. Myocardial Injury After Ischemia/Reperfusion Is Attenuated By Pharmacological Galektin-3 Inhibition. *Sci Rep*. 2019 Dec 1;9(1).

40. Clementy N, Garcia B, André C, Bisson A, Benhenda N, Pierre B, et al. Galektin-3 level predicts response to ablation and outcomes in patients with persistent atrial fibrillation and systolic heart failure. *PLoS One*. 2018 Aug 1;13(8).
41. Falcone C, Lucibell S, Mazzucchellf I, Bozzinf S, SCHIRINZI SI, Totaroi R, et al. Galektin-3 Plasma Levels and Coronary Artery Disease: A New Possible Biomarker Of Acute Coronary Syndrome. Vol. 24, *INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY*.
42. Oyenuga A, Folsom AR, Fashanu O, Aguilar D, Ballantyne CM. Plasma Galektin-3 and Sonographic Measures of Carotid Atherosclerosis in the Atherosclerosis Risk in Communities Study. *Angiology*. 2019 Jan 1;70(1):47–55.
43. Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A, Olaetxea JR, Alloza I, Vandebroek K, et al. Pathophysiology of Atherosclerosis. Vol. 23, *International Journal of Molecular Sciences*. MDPI; 2022.
44. Favero G, Paganelli C, Buffoli B, Rodella LF, Rezzani R. Endothelium and its alterations in cardiovascular diseases: Life style intervention. Vol. 2014, *BioMed Research International*. Hindawi Publishing Corporation; 2014.
45. Berenji Ardestani S, Eftedal I, Pedersen M, Jeppesen PB, Nørregaard R, Matchkov V V. Endothelial dysfunction in small arteries and early signs of atherosclerosis in ApoE knockout rats. *Sci Rep*. 2020 Dec 1;10(1).
46. Esper RJ, Nordaby RA, Vilarinho JO, Paragano A, Cacharrón JL, Machado RA. Endothelial dysfunction: A comprehensive appraisal. *Cardiovasc Diabetol*. 2006 Feb 23;5.
47. Iwakiri T, Yano Y, Sato Y, Hatakeyama K, Marutsuka K, Fujimoto S. Usefulness of carotid intima-media thickness measurement as an indicator of generalized atherosclerosis: findings from autopsy analysis. *Atherosclerosis*. 2012;225(2):359–62. *Atherosclerosis*. 2012;225(2):359–62.
48. Polak JF, Szklo M, Kronmal RA, Burke GL, Shea S, Zavodni AEH, et al. The value of carotid artery plaque and intima-media thickness for incident cardiovascular disease: the multi-ethnic study of atherosclerosis. *J Am Heart Assoc*. 2013;2(2).
49. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, et al. Use of Carotid Ultrasound to Identify Subclinical Vascular Disease and Evaluate Cardiovascular Disease Risk: A Consensus Statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force Endorsed by the Society for Vascular Medicine. Vol. 21, *Journal of the American Society of Echocardiography*. Mosby Inc.; 2008. p. 93–111.
50. Wright RD, Souza PR, Flak MB, Thedchanamoorthy P, Norling LV, Cooper D. Galektin-3-null mice display defective neutrophil clearance during acute inflammation. *J Leukoc Biol*. 2017;101(3):717–26. *J Leukoc Biol*. 2017;101(3):717–26.

51. Soeki T, Sata M. Inflammatory Biomarkers and Atherosclerosis.
52. Pugliese G, Iacobini C, Fantauzzi CB, Menini S. The dark and bright side of atherosclerotic calcification. *Atherosclerosis*. 2015;238(2):220–30.
53. Ou HC, Chou WC, Hung CH, Chu PM, Hsieh PL, Chan SH. Galectin-3 aggravates ox-LDL-induced endothelial dysfunction through LOX-1 mediated signaling pathway. *Environ Toxicol*. 2019;34(7):825–35.
54. Papaspyridonos M, McNeill E, De Bono JP, Smith A, Burnand KG, Channon KM, et al. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. *Arterioscler Thromb Vasc Biol*. 2008 Mar 1;28(3):433–40.
55. Lee YJ, Koh YS, Park HE, Lee HJ, Hwang BH, Kang MK, et al. Spatial and temporal expression, and statin responsiveness of galectin-1 and galectin-3 in murine atherosclerosis. *Korean Circ J*. 2013;43(4):223–30.
56. Zhu W, Sano H, Nagai R, Fukuhara K, Miyazaki A, Horiuchi S. The role of galectin-3 in endocytosis of advanced glycation end products and modified low density lipoproteins. *Biochem Biophys Res Commun*. 2001;280(4):1183–8.
57. Marin-Royo G, Gallardo I, Inez EMM, Gutiérrez B, Jurado-López R, López-Andrés N, et al. Inhibition of galectin-3 ameliorates the consequences of cardiac lipotoxicity in a rat model of diet-induced obesity. *DMM Disease Models and Mechanisms*. 2018 Feb 1;11(2).
58. Tian L, Chen K, Cao J, Gao L. Galectin-3 induces the phenotype transformation of human vascular smooth muscle cells via the canonical Wnt signaling. *Mol Med Rep*. 2017;15(6):3840–6.
59. Menini S, Iacobini C, Ricci C, Fantauzzi CB, Salvi L, Pesce CM, et al. The galectin-3/RAGE dyad modulates vascular osteogenesis in atherosclerosis. *Cardiovasc Res*. 2013 Dec 1;100(3):472–80.
60. Yu L, Ruifrok WPT, Meissner M, Bos EM, Van Goor H, Sanjabi B, et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. *Circ Heart Fail*. 2013 Jan;6(1):107–17.
61. Watson AMD, Li J, Samijono D, Bierhaus A, Thomas MC, Jandeleit-Dahm KAM. . Quinapril treatment abolishes diabetes-associated atherosclerosis in RAGE/apolipoprotein E double knockout mice. *Atherosclerosis*. 2014;235(2):444 - 448. *Atherosclerosis*. 2014;235(2):444-448.
62. Iacobini C, Menini S, Ricci C, Scipioni A, Sansoni V, Cordone S, et al. Accelerated lipid-induced atherogenesis in galectin-3-deficient mice: Role of lipoxidation via receptor-mediated mechanisms. *Arterioscler Thromb Vasc Biol*. 2009 Jun;29(6):831–6.
63. Sharma UC, Mosleh W, Chaudhari MR, Katkar R, Weil B, Evelo C, et al. Myocardial and

- Serum Galektin-3 Expression Dynamics Marks Post-Myocardial Infarction Cardiac Remodelling. *Heart Lung Circ.* 2017 Jul 1;26(7):736–45.
64. De Boer RA, Voors AA, Muntendam P, Van Gilst WH, Van Veldhuisen DJ. Galektin-3: A novel mediator of heart failure development and progression. Vol. 11, *European Journal of Heart Failure*. Oxford University Press; 2009. p. 811–7.
 65. van der Velde AR, Lexis CPH, Meijers WC, van der Horst IC, Lipsic E, Dokter MM. Galektin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction. *Clinica chimica acta.* 2015;2016;15;452:50-57.
 66. Di Tano G, Caretta G, De Maria R, Parolini M, Bassi L, Testa S, et al. Galektin-3 predicts sleft ventricular remodelling after anterior-wall myocardial infarction treated by primary percutaneous coronary intervention. *Heart.* 2017;103(1):71–7.
 67. Singaas EG, Manhenke CA, Dickstein K, Orn S. Circulating Galektin-3 Levels Are Increased in Patients with Ischemic Heart Disease, but Are Not Influenced by Acute Myocardial Infarction. *Cardiology (Switzerland).* 2016 Apr 27;134(4):398–405.
 68. Catapano AL, Graham I, De Backer G, Wiklund O, John Chapman M, Drexel H, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Vol. 37, *European Heart Journal*. Oxford University Press; 2016. p. 2999–3058l.
 69. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Vol. 140, *Circulation*. NLM (Medline); 2019. p. e596–646.
 70. Slack RJ, Mills R, Mackinnon AC. The therapeutic potential of galektin-3 inhibition in fibrotic disease. *International Journal of Biochemistry and Cell Biology.* 2021 Jan 1;130.
 71. Chalasani N, Abdelmalek MF, Garcia-Tsao G, Vuppalanchi R, Alkhouri N, Rinella M, et al. Effects of Belapectin, an Inhibitor of Galektin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension. *Gastroenterology.* 2020 Apr 1;158(5):1334-1345.e5.
 72. Perez-Gomez MV, Sanchez-Niño MD, Sanz AB, Zheng B, Martín-Cleary C, Ruiz-Ortega M, et al. Targeting inflammation in diabetic kidney disease: early clinical trials. *Expert Opin Investig Drugs.* 2016 Sep 1;25(9):1045–58.
 73. Septia N, Wungouw S, Doda V. Hubungan merokok dengan saturasi oksigen pada pegawai di fakultas kedokteran universitas Sam Ratulangi Manado. *J. Jurnal e-Biomedik (eBm).* 2016;4(2).
 74. Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association. *Circulation.* 2022 Feb 22;145.

75. Bress AP, Colantonio LD, Booth JN, Spruill TM, Ravenell J, Butler M, et al. Modifiable Risk Factors Versus Age on Developing High Predicted Cardiovascular Disease Risk in Blacks. *J Am Heart Assoc.* 2017 Feb 2;6.
76. Ferencik M, Mayrhofer T, Bittner DO, Emami H, Puchner SB, Lu MT, et al. Use of high-risk coronary atherosclerotic plaque detection for risk stratification of patients with stable chest pain: A secondary analysis of the promise randomized clinical trial. *JAMA Cardiol.* 2018 Feb 1;3:144–52.
77. Schaefer EJ, Ikezaki H, Diffenderfer MR, Lim E, Liu CT, Hoogeveen RC, et al. Atherosclerotic cardiovascular disease risk and small dense low-density lipoprotein cholesterol in men, women, African Americans and non-African Americans: The pooling project. *Atherosclerosis.* 2023 Feb 1;367:15–23.
78. Maharani A, Sujarwoto, Praveen D, Oceandy D, Tampubolon G, Patel A. Cardiovascular disease risk factor prevalence and estimated 10-year cardiovascular risk scores in Indonesia: The SMARThealth Extend study. *PLoS One.* 2019 Apr 1;14.
79. Wong ND, Budoff MJ, Ferdinand K, Graham IM, Michos ED, Reddy T, et al. Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement. *Am J Prev Cardiol.* 2022;10:100335.
80. Kwak S, Lee HJ, Kim S, Park JB, Lee SP, Kim HK, et al. Machine learning reveals sex-specific associations between cardiovascular risk factors and incident atherosclerotic cardiovascular disease. *Sci Rep.* 2023 Dec 1;13.
81. Pagidipati NJ, Zheng Y, Green JB, McGuire DK, Mentz RJ, Shah S, et al. Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS. *Am Heart J.* 2020 Jan 1;219:47–57.
82. Kotlyarov S. The Role of Smoking in the Mechanisms of Development of Chronic Obstructive Pulmonary Disease and Atherosclerosis. Vol. 24, *International Journal of Molecular Sciences*. Multidisciplinary Digital Publishing Institute (MDPI); 2023.
83. Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: Cardiovascular disease in diabetes mellitus. Vol. 133, *Circulation*. Lippincott Williams and Wilkins; 2016. p. 2459–502.
84. Zhou Y, Zhang R, Wang G, Wang A, Zhong C, Zhang M, et al. Coexistence effect of hypertension and angiotensin II on the risk of coronary heart disease: a population-based prospective cohort study among Inner Mongolians in China. *Curr Med Res Opin.* 2019 Aug 3;35:1473–8.
85. Nakanishi R, Baskaran L, Gransar H, Budoff MJ, Achenbach S, Al-Mallah M, et al. Relationship of Hypertension to Coronary Atherosclerosis and Cardiac Events in Patients with Coronary Computed Tomographic Angiography. *Hypertension.* 2017 Aug 1;70:293–9.

86. Zhou YY, Qiu HM, Yang Y, Han YY. Analysis of risk factors for carotid intima-media thickness in patients with type 2 diabetes mellitus in Western China assessed by logistic regression combined with a decision tree model. *Diabetol Metab Syndr*. 2020 Jan 28;12.
87. van den Munckhof ICL, Jones H, Hopman MTE, de Graaf J, Nyakayiru J, van Dijk B, et al. Relation between age and carotid artery intima-medial thickness: a systematic review. Vol. 41, *Clinical Cardiology*. John Wiley and Sons Inc.; 2018. p. 698–704.
88. Zyriax BC, Dransfeld K, Windler E. Carotid intima–media thickness and cardiovascular risk factors in healthy volunteers. *Ultrasound Journal*. 2021 Dec 1;13.
89. Kim K II. Risk Stratification of Cardiovascular Disease according to Age Groups in New Prevention Guidelines: A Review. *J Lipid Atheroscler*. 2023 May 1;12:96–105.
90. Branch M, German C, Bertoni A, Yeboah J. Incremental risk of cardiovascular disease and/or chronic kidney disease for future ASCVD and mortality in patients with type 2 diabetes mellitus: ACCORD trial. *J Diabetes Complications*. 2019 Jul 1;33:468–72.
91. Jin QH, Lou YF, Li TL, Chen HH, Liu Q, He XJ. Serum galectin-3: A risk factor for vascular complications in type 2 diabetes mellitus. *Chin Med J (Engl)*. 2013;126:2109–15.
92. Suzuki Y, Inoue T, Yoshimaru T, Ra C. Galectin-3 but not galectin-1 induces mast cell death by oxidative stress and mitochondrial permeability transition. *Biochim Biophys Acta Mol Cell Res*. 2008;1783:924–34.
93. Naylor M, Wang N, Larson MG, Vasan RS, Levy D, Ho JE. Circulating galectin-3 is associated with cardiometabolic disease in the community. *J Am Heart Assoc*. 2016;5:1–7.
94. Li Y, Li T, Zhou Z, Xiao Y. Emerging roles of Galectin-3 in diabetes and diabetes complications: A snapshot. *Rev Endocr Metab Disord*. 2022;23:569–77.
95. Dong T, Li H, Wang S, Chen W. Efficacy evaluation of serum galectin-3 in hypertension complicated with diastolic dysfunction. *Exp Ther Med*. 2019;147–52.
96. Mitić B, Jovanović A, Nikolić VN, Stokanović D, Andrejić OM, Vučić RM, et al. Trend of Galectin-3 Levels in Patients with Non-ST-Elevation and ST-Elevation Myocardial Infarction. *Medicina (Lithuania)*. 2022;58:1–13.
97. Nurjannah N, Nurahmi N, Kurniawan LB. Correlation Analysis of Galectin-3 Serum Level in Obesity with and without Obesity. *Indonesian Journal of Clinical Pathology and Medical Laboratory*. 2023;29:216–9.
98. Aguilar D, Sun C, Hoogeveen RC, Nambi V, Selvin E, Matsushita K, et al. Levels and change in galectin-3 and association with cardiovascular events: The aric study. *J Am Heart Assoc*. 2020;9.
99. Kasacka I, Piotrowska Z, Niezgodą M, Lewandowska A, Łebkowski W. Ageing-related changes in the levels of β -catenin, CacyBP/SIP, galectin-3 and immunoproteasome

- subunit LMP7 in the heart of men. *PLoS One*. 2020;15:1–17.
100. de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, et al. The fibrosis marker galektin-3 and outcome in the general population. *J Intern Med*. 2012;272:55–64.
 101. Pei CZ, Wang X, Lin Y, Fang L, Meng S. Inhibition of Galektin-3 Alleviates Cigarette Smoke Extract-Induced Autophagy and Dysfunction in Endothelial Progenitor Cells. *Oxid Med Cell Longev*. 2019;2019.
 102. de Oliveira FL, Gatto M, Bassi N, Luisetto R, Ghirardello A, Punzi L, et al. Galektin-3 in autoimmunity and autoimmune diseases. *Exp Biol Med*. 2015;240:1019–28.
 103. Sadlonova M, Meyer T, Binder L, Wachter R, Edelmann F, Herrmann-Lingen C. Higher galektin-3 levels are independently associated with lower anxiety in patients with risk factors for heart failure. *Biopsychosoc Med*. 2020;14:1–8.
 104. Li H, Xu X, Luo B, Zhang Y. The Predictive Value of Carotid Ultrasonography With Cardiovascular Risk Factors—A “SPIDER” Promoting Atherosclerosis. Vol. 8, *Frontiers in Cardiovascular Medicine*. Frontiers Media SA; 2021.
 105. Johnsen SH, Mathiesen EB, Joakimsen O, Stensland E, Wilsgaard T, Løchen ML, et al. Carotid atherosclerosis is a stronger predictor of myocardial infarction in women than in men: A 6-year follow-up study of 6226 persons: The Tromsø study. *Stroke*. 2007 Nov;38:2873–80.
 106. AlQuaiz AJM, Kazi A, Alodhayani AA, Almeneessier A, AlHabeeb KM, Siddiqui AR. Age and gender differences in the prevalence of chronic diseases and atherosclerotic cardiovascular disease risk scores in adults in Riyadh city, Saudi Arabia. *Saudi Med J*. 2021;42:0.
 107. Garcia M, Mulvagh SL, Noel C, Merz B, Buring JE, Manson JE. Cardiovascular Disease in Women: Clinical Perspectives HHS Public Access. *Circ Res* April. 2016;15:1273–93.
 108. George J, Rapsomaniki E, Pujades-Rodriguez M, Shah AD, Denaxas S, Herrett E, et al. How does cardiovascular disease first present in women and men? *Circulation*. 2015;132:1320–8.
 109. Curtis AB, Karki R, Hattoum A, Sharma UC. Arrhythmias in Patients ≥ 80 Years of Age: Pathophysiology, Management, and Outcomes. *J Am Coll Cardiol*. 2018;71:2041–57.
 110. Chung KW. Advances in understanding of the role of lipid metabolism in aging. *Cells*. 2021;10.
 111. Gallo G, Volpe M, Savoia C. Endothelial Dysfunction in Hypertension: Current Concepts and Clinical Implications. *Front Med (Lausanne)*. 2022;8:1–8.
 112. Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. *Cardiovasc Diabetol*.

- 2018;17:1–14.
113. Fowler MJ. Microvascular and macrovascular complications of diabetes. *Clinical Diabetes*. 2011;29:116–22.
 114. Hedayatnia M, Asadi Z, Zare-Feyzabadi R, Yaghooti-Khorasani M, Ghazizadeh H, Ghaffarian-Zirak R, et al. Dyslipidemia and cardiovascular disease risk among the MASHAD study population. *Lipids Health Dis*. 2020;19:1–11.
 115. Hsuan CF, Lin FJ, Lee TL, Yang KC, Tseng WK, Wu YW, et al. The waist-to-body mass index ratio as an anthropometric predictor for cardiovascular outcome in subjects with established atherosclerotic cardiovascular disease. *Sci Rep*. 2022;12:1–10.
 116. Barroso TA, Marins LB, Alves R, Gonçalves ACS, Barroso SG, Rocha G de S. Association of Central Obesity with The Incidence of Cardiovascular Diseases and Risk Factors. *International Journal of Cardiovascular Sciences*. 2017;30:416–24.
 117. Khan SS, Ning H, Sinha A, Wilkins J, Allen NB, Vu THT, et al. Cigarette smoking and competing risks for fatal and nonfatal cardiovascular disease subtypes across the life course. *J Am Heart Assoc*. 2021;10.
 118. Barua RS, Ambrose JA. Mechanisms of coronary thrombosis in cigarette smoke exposure. *Arterioscler Thromb Vasc Biol*. 2013;33:1460–7.
 119. Gallucci G, Tartarone A, Lerosé R, Lalinga AV, Capobianco AM. Cardiovascular risk of smoking and benefits of smoking cessation. *J Thorac Dis*. 2020;12:3866–76.
 120. Sciacchitano S, Lavra L, Morgante A, Olivieri A, Magi F, De Francesco GP, et al. Galektin-3: One molecule for an alphabet of diseases, from A to Z. *Int J Mol Sci*. 2018;19.
 121. Oyenuga A, Folsom AR, Fashanu O, Aguilar D, Ballantyne CM. Plasma Galektin-3 and Sonographic Measures of Carotid Atherosclerosis in the Atherosclerosis Risk in Communities Study. *Angiology*. 2019 Jan 7;70:47–55.
 122. Ozturk D, Celik O, Satilmis S, Aslan S, Erturk M, Cakmak HA, et al. Association between serum galektin-3 levels and coronary atherosclerosis and plaque burden/structure in patients with type 2 diabetes mellitus. *Coron Artery Dis*. 2015;26:396–401.
 123. Świącki P, Sawicki R, Knapp M, Kamiński KA, Ptaszyńska-Kopczyńska K, Sobkowicz B, et al. Galektin-3 as the prognostic factor of adverse cardiovascular events in long-term follow up in patients after myocardial infarction—a pilot study. *J Clin Med*. 2020 Jun 1;9.
 124. Lisowska A, Knapp M, Tycińska A, Motybel E, Kamiński K, Świecki P, et al. Predictive value of Galektin-3 for the occurrence of coronary artery disease and prognosis after myocardial infarction and its association with carotid IMT values in these patients: A mid-term prospective cohort study. *Atherosclerosis*. 2016;246:309–17.
 125. Lee YJ, Koh YS, Park HE, Lee HJ, Hwang BH, Kang MK, et al. Spatial and temporal expression, and statin responsiveness of galectin-1 and galectin-3 in murine atherosclerosis. *Korean Circ J*. 2013;43:223–30.

126. Gao Z, Liu Z, Wang R, Zheng Y, Li H, Yang L. Galektin-3 Is a Potential Mediator for Atherosclerosis. *J Immunol Res.* 2020;2020.
127. Iacobini C, Menini S, Ricci C, Scipioni A, Sansoni V, Cordone S, et al. Accelerated lipid-induced atherogenesis in galektin-3-deficient mice: Role of lipoxidation via receptor- mediated mechanisms. *Arterioscler Thromb Vasc Biol.* 2009;29:831–6.
128. Kadoglou NPE, Sfyroeras GS, Spathis A, Gkekas C, Gastounioti A, Mantas G, et al. Galektin-3, carotid plaque vulnerability, and potential effects of statin therapy. *EuropeanJournal of Vascular and Endovascular Surgery.* 2015;49:4–9.

